A quality assurance audit: Phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01)

SUMMARY In 1997 the Trans‐Tasman Radiation Oncology Group (TROG) performed a quality assurance (QA) audit of its phase III randomized clinical trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally adv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Australasian radiology 2000-02, Vol.44 (1), p.65-71
Hauptverfasser:	Steigler, A, Mameghan, H, Lamb, D, Joseph, D, Matthews, J, Franklin, I, Turner, S, Spry, N, Poulsen, M, North, J, Kovacev, O, Denham, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Costs and Cost Analysis Flutamide - therapeutic use Goserelin - therapeutic use hormones Humans Male Medical Audit - economics phase III trial planning techniques prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy quality assurance Quality Assurance, Health Care Radiotherapy, Adjuvant Time Factors trial budget
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!